VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
Journal of Clinical Oncology · 20.04.2026 · 44 (12) · 1108-1119
DOI: 10.1200/jco-25-02643 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2026. Verfasst von Sara A Hurvitz und 26 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in early clinical trials with palbociclib and fulvestrant. METHODS This phase III randomized trial (VIKTORIA-1; ClinicalTrials.gov identifier: NCT05501886 ) evaluated the efficacy of gedatolisib-based therapy, comparing gedatolisib, palbociclib, and fulvestrant (gedatolisib triplet) and gedatolisib plus fulvestrant (gedatolisib doublet) with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HER2−), PIK3CA wild-type (WT) advanced breast cancer. Eligible patients had disease progression during or after CDK4/6 inhibitor and aromatase inhibitor treatment. Comparison of progression-free survival as assessed by blinded independent central review for gedatolisib triplet versus fulvestrant and gedatolisib doublet versus fulvestrant was the primary objective. RESULTS A total of 392 patients were randomly assigned 1:1:1. The median study follow-up was 10.1 months. The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant). Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients. CONCLUSION The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor–positive/HER2−, PIK3CA WT advanced breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Istituto Europeo di Oncologia, IRCCS, Milano, Italy.
- University of Milano, Milano, Italy.
- Gustave Roussy, Villejuif, France.
- Weill Cornell Medical College, New York, NY.
ORCID-Profile: Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, Fabrice André, Massimo Cristofanilli, Sung-Bae Kim, Jorge Luis Martínez Rodríguez, Jorge C Nadal, Gun Min Kim, Yuly A Remolina-Bonilla, Geronimo Rosselli, George Emile, Robert Wesolowski, Miguel Martin, Alistair Ring, Antonio Giordano, Sarah C Mutka, Keren Moss, Sam Suzuki, Barbara Pistilli
Zitieren
APA
Hurvitz, S. A., Layman, R. M., Curigliano, G., André, F., Cristofanilli, M., Kim, S. B., Martínez Rodríguez, J. L., Nadal, J. C., Kim, G. M., Lo, L., Remolina-Bonilla, Y. A., Rosselli, G., Emile, G., Korbenfeld, E., Puig, J. M., Wesolowski, R., Martin, M., Ring, A., Han, H. S., …, & VIKTORIA-1 Study Group (2026). VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer. Journal of Clinical Oncology, 44(12), 1108-1119. https://doi.org/10.1200/jco-25-02643
Vancouver
Hurvitz SA, Layman RM, Curigliano G, André F, Cristofanilli M, Kim SB, et al. VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer. Journal of Clinical Oncology. 2026;44(12):1108-1119. doi:10.1200/jco-25-02643
BibTeX
@article{Hurvitz2026,
author = {Hurvitz, Sara A and Layman, Rachel M and Curigliano, Giuseppe and André, Fabrice and Cristofanilli, Massimo and Kim, Sung-Bae and Martínez Rodríguez, Jorge Luis and Nadal, Jorge C and Kim, Gun Min and Lo, Louisa and Remolina-Bonilla, Yuly A and Rosselli, Geronimo and Emile, George and Korbenfeld, Ernesto and Puig, Juan Manuel and Wesolowski, Robert and Martin, Miguel and Ring, Alistair and Han, Hyo S and Giordano, Antonio and Mutka, Sarah C and Moss, Keren and Suzuki, Sam and Sullivan, Brian and Gorbatchevsky, Igor and Pistilli, Barbara and VIKTORIA-1 Study Group, VIKTORIA-1 Study Group},
title = {VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {12},
pages = {1108--1119},
doi = {10.1200/jco-25-02643}
}
EUVIMED